GACM
ALXN

Green Arrow Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Green Arrow Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-10,000
Closed -$1.52M – 267
2014
Q1 		$1.52M Sell
10,000
-7,233
-42% -$1.15M 0.13% 164
2013
Q4 		$2.29M Buy
+17,233
New +$2.07M 0.16% 163
2013
Q3 		– Sell
-38,000
Closed -$3.5M – 316
2013
Q2 		$3.5M Buy
+38,000
New +$3.66M 0.28% 112

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Green Arrow Capital Management's ALXN Position: Q2 2014 in Review

Green Arrow Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2014, closing a stake of 10,000 shares — an estimated $1.52M sold.

Green Arrow Capital Management first reported a position in ALXN in Q2 2013 and held it in 3 quarters. The position peaked at $3.5M in Q2 2013. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

  • Green Arrow Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Green Arrow Capital Management sold 10,000 Alexion Pharmaceuticals shares in Q2 2014, an estimated $1.52M.
  • Green Arrow Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Green Arrow Capital Management's Alexion Pharmaceuticals position peaked at $3.5M in Q2 2013.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on Green Arrow Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.